Share on StockTwits

Investment analysts at Jefferies Group began coverage on shares of Allergan (NYSE:AGN) in a note issued to investors on Monday, reports. The firm set a “hold” rating and a $139.00 price target on the stock. Jefferies Group’s price target suggests a potential downside of 15.06% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at Sterne Agee initiated coverage on shares of Allergan in a research note on Wednesday, April 16th. They set a “buy” rating and a $142.00 price target on the stock. Separately, analysts at Zacks downgraded shares of Allergan from an “outperform” rating to a “neutral” rating in a research note on Monday, April 7th. They now have a $130.00 price target on the stock. Finally, analysts at Citigroup Inc. raised their price target on shares of Allergan from $130.00 to $140.00 in a research note on Friday, March 28th. They now have a “buy” rating on the stock. Nine equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $128.67.

Shares of Allergan (NYSE:AGN) traded up 15.25% on Monday, hitting $163.65. The stock had a trading volume of 32,434,174 shares. Allergan has a 1-year low of $81.33 and a 1-year high of $165.45. The stock has a 50-day moving average of $127.3 and a 200-day moving average of $110.8. The company has a market cap of $48.844 billion and a price-to-earnings ratio of 43.56.

Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $1.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.34 by $0.22. The company had revenue of $1.66 million for the quarter, compared to the consensus estimate of $1.65 million. During the same quarter in the previous year, the company posted $1.15 earnings per share. The company’s revenue for the quarter was up 14.4% on a year-over-year basis. On average, analysts predict that Allergan will post $5.47 earnings per share for the current fiscal year.

Allergan, Inc is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.